IE44522B1 - Novel crystalline forms of prazosin hydrochloride - Google Patents

Novel crystalline forms of prazosin hydrochloride

Info

Publication number
IE44522B1
IE44522B1 IE399/77A IE39977A IE44522B1 IE 44522 B1 IE44522 B1 IE 44522B1 IE 399/77 A IE399/77 A IE 399/77A IE 39977 A IE39977 A IE 39977A IE 44522 B1 IE44522 B1 IE 44522B1
Authority
IE
Ireland
Prior art keywords
prazosin hydrochloride
hydrochloride
prazosin
kelly
crystalline
Prior art date
Application number
IE399/77A
Other languages
English (en)
Other versions
IE44522L (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IE44522L publication Critical patent/IE44522L/xx
Publication of IE44522B1 publication Critical patent/IE44522B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
IE399/77A 1976-03-01 1977-02-24 Novel crystalline forms of prazosin hydrochloride IE44522B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/662,937 US4092315A (en) 1976-03-01 1976-03-01 Novel crystalline forms of prazosin hydrochloride

Publications (2)

Publication Number Publication Date
IE44522L IE44522L (en) 1977-09-01
IE44522B1 true IE44522B1 (en) 1981-12-30

Family

ID=24659839

Family Applications (1)

Application Number Title Priority Date Filing Date
IE399/77A IE44522B1 (en) 1976-03-01 1977-02-24 Novel crystalline forms of prazosin hydrochloride

Country Status (32)

Country Link
US (1) US4092315A (OSRAM)
JP (1) JPS604188B2 (OSRAM)
AR (1) AR210937A1 (OSRAM)
AU (1) AU506937B2 (OSRAM)
BE (1) BE851878A (OSRAM)
BG (1) BG29724A3 (OSRAM)
CA (1) CA1068269A (OSRAM)
CH (1) CH618436A5 (OSRAM)
CS (1) CS191332B2 (OSRAM)
DD (1) DD129652A5 (OSRAM)
DE (1) DE2708192C3 (OSRAM)
DK (1) DK145858C (OSRAM)
ES (1) ES8707447A1 (OSRAM)
FI (1) FI62082C (OSRAM)
FR (1) FR2372828A1 (OSRAM)
GB (1) GB1538713A (OSRAM)
HK (1) HK30881A (OSRAM)
HU (1) HU173641B (OSRAM)
IE (1) IE44522B1 (OSRAM)
IL (1) IL51481A (OSRAM)
LU (1) LU76868A1 (OSRAM)
MY (1) MY8100271A (OSRAM)
NL (1) NL169591C (OSRAM)
NO (1) NO146499C (OSRAM)
NZ (1) NZ183450A (OSRAM)
PL (1) PL105559B1 (OSRAM)
PT (1) PT66227B (OSRAM)
RO (1) RO73095A (OSRAM)
SE (1) SE423234B (OSRAM)
SU (1) SU644387A3 (OSRAM)
YU (1) YU41294B (OSRAM)
ZA (1) ZA77918B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX5483E (es) * 1977-08-04 1983-08-23 Abbott Lab Procedimiento para la preparacion del dihidrato clorhidrato de 1-(4-amino-6,7-dimetoxi-2-quinazolinil)-4-(2-tetrahidrofuroil)piperazina
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
US4197301A (en) * 1978-10-16 1980-04-08 Allergan Pharmaceuticals, Inc. Topical ophthalmic use of Prazosin
FI67699C (fi) * 1979-01-31 1985-05-10 Orion Yhtymae Oy Foerfarande foer framstaellning av 6,7-dimetoxi-4-amino-2-(4-(2-furoyl)-1-piperazinyl)kinazolinhydroklorid med blodtryckssaenkande verkan
US4440769A (en) * 1983-02-11 1984-04-03 Abbott Laboratories 2-(4-Phenylalkanoylpiperazin-1-yl) quinazoline compounds, pharmaceutical compositions and method of producing α1 antagonistic activity
FI79107C (fi) * 1984-06-25 1989-11-10 Orion Yhtymae Oy Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.
US5322943A (en) * 1985-09-12 1994-06-21 The Upjohn Company Piperazine compounds which are substituted
US4601897A (en) * 1985-11-06 1986-07-22 Pfizer Inc. Prazosin-pirbuterol combination for bronchodilation
DE3683760D1 (de) * 1986-03-21 1992-03-12 Heumann Pharma Gmbh & Co Kristalline, wasserfreie sigma -form von 2-(4-(2-furoyl-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung.
US5110927A (en) * 1987-12-31 1992-05-05 The United States Of America As Represented By The Department Of Health And Human Services Prazosin analog with increased selectivity and duration of action
JP2652272B2 (ja) * 1990-12-31 1997-09-10 住化ファインケム株式会社 １−（４−アミノ−６，７−ジメトキシ−２−キナゾリニル）−４−（２−テトラヒドロフロイル）ピペラジン塩酸塩の新規な結晶体および該結晶体の製造方法
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
DK0849266T3 (da) * 1996-12-20 2007-06-04 Heumann Pcs Gmbh Hidtil ukendt polymorf form af doxazosin-mesylat (form III)
EP0849264A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von doxazosinmesylat (Form I)
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
EP3172377B1 (en) 2014-07-21 2018-09-12 KEIR Manufacturing, Inc. Aerodynamic flyer bow

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663706A (en) * 1969-09-29 1972-05-16 Pfizer Use of 2,4-diaminoquinazolines as hypotensive agents

Also Published As

Publication number Publication date
GB1538713A (en) 1979-01-24
RO73095A (ro) 1981-06-26
LU76868A1 (OSRAM) 1977-09-21
CA1068269A (en) 1979-12-18
NL169591B (nl) 1982-03-01
YU49977A (en) 1983-12-31
IL51481A (en) 1980-09-16
HK30881A (en) 1981-07-10
DE2708192A1 (de) 1977-09-08
NL169591C (nl) 1982-08-02
FR2372828B1 (OSRAM) 1980-02-01
ZA77918B (en) 1977-12-28
BE851878A (fr) 1977-08-29
DK86877A (da) 1977-09-02
IL51481A0 (en) 1977-04-29
DK145858C (da) 1983-09-12
ES8707447A1 (es) 1987-08-16
FR2372828A1 (fr) 1978-06-30
CH618436A5 (OSRAM) 1980-07-31
IE44522L (en) 1977-09-01
FI770634A7 (OSRAM) 1977-09-02
YU41294B (en) 1987-02-28
SE423234B (sv) 1982-04-26
NL7702123A (nl) 1977-09-05
MY8100271A (en) 1981-12-31
DD129652A5 (de) 1978-02-01
FI62082B (fi) 1982-07-30
DE2708192C3 (de) 1980-05-08
NZ183450A (en) 1979-03-16
US4092315A (en) 1978-05-30
HU173641B (en) 1979-07-28
NO770674L (no) 1977-09-02
JPS604188B2 (ja) 1985-02-01
AU2244377A (en) 1978-11-23
PL105559B1 (pl) 1979-10-31
PT66227A (en) 1977-03-01
SU644387A3 (ru) 1979-01-25
NO146499B (no) 1982-07-05
DK145858B (da) 1983-03-21
AU506937B2 (en) 1980-01-31
BG29724A3 (bg) 1981-01-15
ES545368A0 (es) 1978-06-01
JPS52105206A (en) 1977-09-03
FI62082C (fi) 1982-11-10
SE7701624L (sv) 1977-09-02
PL196354A1 (pl) 1978-02-27
CS191332B2 (en) 1979-06-29
NO146499C (no) 1982-10-13
DE2708192B2 (de) 1979-08-02
AR210937A1 (es) 1977-09-30
PT66227B (en) 1978-07-14

Similar Documents

Publication Publication Date Title
IE44522B1 (en) Novel crystalline forms of prazosin hydrochloride
JP2018522877A (ja) （Ｓ）−４−（８−アミノ−３−（１−（ブト−２−イノイル）ピロリジン−２−イル）イミダゾ［１，５−ａ］ピラジン−１−イル）−Ｎ−（ピリジン−２−イル）ベンザミドの固体形態及び製剤
BRPI0707604A2 (pt) formas de tricloridrato de derivado de diidropteridinona e processos para preparaÇço
EP4303212B1 (en) Hydroxytyrosol nicotinamide eutectic crystal, and preparation method therefor and composition thereof
HUE026726T2 (en) Crystalline naloxol-PEG conjugate
JP2012512145A (ja) フリバンセリンの結晶性の塩形態
TW420678B (en) New polymerphic form of doxazosin mesylate (Form I)
US7618976B2 (en) Methods for the production of sildenafil base and citrate salt
JP2021523880A (ja) ジヒドロピリミジン化合物の固体形態及びその調製方法及びその使用
RU2182575C2 (ru) Псевдополиморфные формы дигидрохлорида 2-[2-[4-(бис-(4-фторфенил)метил)-1-пиперазинил]этокси]уксусной кислоты
JP2023540056A (ja) カリプラジン薬用塩及びその結晶形、製造方法及び応用
EP1295870B1 (en) Suplatast tosilate crystals
CN119528805A (zh) 吡非尼酮共晶及其制备方法、药物组合物与用途
US20230339918A1 (en) Crystal forms of crenolanib and methods of use thereof
US10947185B2 (en) Crystal form of dezocine and preparation method therefor
EP3083552B1 (en) Stable solid forms of enclomiphene and enclomiphene citrate
WO2023160542A1 (zh) 二肽基肽酶抑制剂化合物的盐及晶型
KR810000956B1 (ko) 프라조신 염산염의 α형의 제조방법
US20190119239A1 (en) Crystal form of tasimelteon
WO2023143350A1 (zh) 吩噻嗪类化合物的晶型、盐、制备方法及用途
EP3034496A1 (en) Novel solvates of n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl]acetamide
JP2023536068A (ja) クレノラニブの結晶形態およびそれを用いる方法
CN120344508A (zh) 苯并恶嗪酮类化合物的结晶及其制备
CN120965762A (zh) 一种布格替尼的晶型及其制备方法和应用
KR20210122140A (ko) (-)-시벤졸린 숙신산염의 결정다형

Legal Events

Date Code Title Description
MK9A Patent expired